Key statistics dashboard for Sutro Biopharma, Inc. (STRO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
Stock Data
| Price | $15.60 |
| Market Cap | $151M |
| Enterprise Value | $107.4M |
| Beta | 1.31 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.91 |
| Price / Book | -2.55 |
| P/S | 3.37 |
| EV/EBITDA | -0.80 |
| EV/Sales | 2.35 |
| EV/FCF | -0.74 |
| P/FCF | -1.06 |
| Earnings Yield | -69.87% |
| FCF Yield | -96.46% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 97.20% |
| EBIT Margin | -307.79% |
| EBITDA Margin | -294.52% |
| Operating Margin | -309.87% |
| Net Margin | -395.25% |
| Return on Equity | 185.30% |
| Return on Assets | -92.89% |
| Return on Invested Capital | -95.49% |
| Return on Capital Employed | -100.04% |
Financial Health
| Current Ratio | 3.32 |
| Quick Ratio | 3.32 |
| Cash Ratio | 1.03 |
| Debt / Equity | -0.10 |
| Debt / Assets | 5.55% |
| Net Debt / EBITDA | 0.32 |
| Interest Coverage | -3.53 |
Per-Share Data
| Revenue per share | 2.76 |
| Book Value per share | -6.23 |
| Cash per share | 9.92 |
| FCF per share | -8.79 |
| Tangible Book Value per share | -6.23 |
| Dividend per share | 0.00 |
Related companies: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explore sector: Healthcare · Biotechnology
More sections of STRO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks